We are proud to be part of the GENEGUT consortium, which just had its 7th general assembly in Uppsala.
Our main goal is to develop a novel drug delivery system for oral gene therapy, targeting Crohn’s disease.
CarboHyde’s contribution is the synthesis of nanoparticle-forming cyclodextrin building blocks, that can efficiently encapsulate and transfect siRNA into endothelial cells.
